Pharmacotherapy of Pompe disease

Bibliography

• Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alfa-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. McGraw-Hill, New York; 2001; p. 3389-420
   Google Scholar
• van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342-53
   PubMed Web of Science ®Google Scholar
• Shea L, Raben N. Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 2009;47(Suppl 1):S42-7
   PubMedGoogle Scholar
• Raben N, Baum R, Schreiner C, et al. When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy 2009;5:111-13
   PubMed Web of Science ®Google Scholar
• Nascimbeni AC, Fanin M, Masiero E, et al. Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy 2012;8:1697-700
   PubMed Web of Science ®Google Scholar
• van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Hwu WL, Mandel H, et al. Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-6
   PubMed Web of Science ®Google Scholar
• Hagemans ML, Winkel LP, Van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-7
   PubMed Web of Science ®Google Scholar
• Parenti G, Pignata C, Vajro P, Salerno M. New strategies for the treatment of lysosomal storage diseases. Int J Mol Med 2013;31:11-20
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Steiner RD, Bali D, et al. Pompe disease diagnosis and management guideline. Genet Med 2006;8:267-88
   PubMed Web of Science ®Google Scholar
• Bembi B, Cerini E, Danesino C, et al. Management and treatment of glycogenosis type II. Neurology 2008;71:S12-36
   Google Scholar
• Case LE, Kishnani PS. Physical therapy management of Pompe disease. Genet Med 2006;8:318-27
   PubMed Web of Science ®Google Scholar
• Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012;45:319-33
   PubMed Web of Science ®Google Scholar
• Nilsson MI, Samjoo IA, Hettinga BP, et al. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. Mol Genet Metab 2012;107:469-79
   Google Scholar
• Bodamer OA, Leonard JV, Halliday D. Dietary treatment in late-onset acid maltase deficiency. Eur J Pediatr 1997;156(Suppl 1):S39-42
   Google Scholar
• Slonim AE, Bulone L, Goldberg T, et al. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve 2007;35:70-7
   PubMed Web of Science ®Google Scholar
• Sly WS. Receptor-mediated transport of acid hydrolases to lysosomes. Curr Top Cell Regul 1985;26:27-38
   Google Scholar
• Bijvoet AG, van de Kamp EH, Kroos MA, et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 1998;7:53-62
   PubMed Web of Science ®Google Scholar
• Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998;273:19086-92
   PubMed Web of Science ®Google Scholar
• McVie-Wylie AJ, Lee KL, Qiu H, et al. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab 2008;94:448-55
   PubMed Web of Science ®Google Scholar
• Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004;113:e448-57
   PubMed Web of Science ®Google Scholar
• Klinge L, Straub V, Neudorf U, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31
   PubMed Web of Science ®Google Scholar
• Levine JC, Kishnani PS, Chen YT, et al. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. Pediatr Cardiol 2008;29:1033-42
   Web of Science ®Google Scholar
• Rossi M, Parenti G, Della Casa R, et al. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. J Child Neurol 2007;22:565-73
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109
   PubMed Web of Science ®Google Scholar
• Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-20
   PubMed Web of Science ®Google Scholar
• Merk T, Wibmer T, Schumann C, Krüger S. Glycogen storage disease type II (Pompe disease)–influence of enzyme replacement therapy in adults. Eur J Neurol 2009;16:247-
   Google Scholar
• Strothotte S, Strigl-Pill N, Grunert B, et al. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010;257:91-7
   PubMed Web of Science ®Google Scholar
• van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-406
   PubMed Web of Science ®Google Scholar
• Byrne BJ, Kishnani PS, Case LE, et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab 2011;103:1-11
   PubMed Web of Science ®Google Scholar
• Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:397-8
   PubMed Web of Science ®Google Scholar
• Chakrapani A, Vellodi A, Robinson P, et al. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 2010;33:747-50
   Web of Science ®Google Scholar
• Case LE, Beckemeyer AA, Kishnani PS. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet 2012;160:69-79
   Google Scholar
• Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012;259:952-8
   PubMed Web of Science ®Google Scholar
• Regnery C, Kornblum C, Hanisch F, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 2012;35:837-45
   PubMed Web of Science ®Google Scholar
• Wyatt K, Henley W, Anderson L, et al. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 2012;16:1-543
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-25
   PubMed Web of Science ®Google Scholar
• Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33
   PubMed Web of Science ®Google Scholar
• Raben N, Danon M, Gilbert AL, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003;80:159-69
   PubMed Web of Science ®Google Scholar
• Wenk J, Hille A, von Figura K. Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int 1991;23:723-31
   PubMedGoogle Scholar
• Cardone M, Porto C, Tarallo A, et al. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 2008;1:6
   Google Scholar
• Fukuda T, Ahearn M, Roberts A, et al. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 2006;14:831-9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Jiang JL, Gumlaw NK, et al. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther 2009;17:954-63
   PubMed Web of Science ®Google Scholar
• Tiels P, Baranova E, Piens K, et al. A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes. Nat Biotechnol 2012;30:1225-31
   PubMedGoogle Scholar
• Maga JA, Zhou J, Kambampati R, et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 2013;288:1428-38
   PubMed Web of Science ®Google Scholar
• Hsu J, Northrup L, Bhowmick T, Muro S. Enhanced delivery of alpha-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine 2012;8:731-9
   PubMed Web of Science ®Google Scholar
• Beutler E. Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 2006;88:208-15
   PubMed Web of Science ®Google Scholar
• Aviezer D, Brill-Almon E, Shaaltiel Y, et al. A plant-derived recombinant human glucocerebrosidase enzyme. A preclinical and phase I investigation. PLoS ONE 2009;4:e4792
   PubMed Web of Science ®Google Scholar
• Koeberl DD, Li S, Dai J, et al. beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab 2012;105:221-7
   PubMed Web of Science ®Google Scholar
• Li S, Sun B, Nilsson MI, et al. Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J 2013;27:34-44
   PubMed Web of Science ®Google Scholar
• Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med 2009;360:194-5
   PubMed Web of Science ®Google Scholar
• Banugaria SG, Prater SN, McGann JK, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 2013;15:123-31
   PubMed Web of Science ®Google Scholar
• Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14:135-42
   PubMed Web of Science ®Google Scholar
• Cousens L, Mingozzi F, van der Marel S, et al. Teaching tolerance: new approaches to enzyme replacement therapy for Pompe disease. Hum Vaccin Immunother 2012;8:1459-64
   PubMed Web of Science ®Google Scholar
• Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-15
   PubMed Web of Science ®Google Scholar
• Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009;1:268-79
   PubMed Web of Science ®Google Scholar
• Valenzano KJ, Khanna R, Powe AC, et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev Technol 2011;9:213-35
   PubMed Web of Science ®Google Scholar
• Sugawara K, Saito S, Sekijima M, et al. Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease. J Hum Genet 2009;54:324-30
   PubMed Web of Science ®Google Scholar
• Yoshimizu M, Tajima Y, Matsuzawa F, et al. Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism. Clin Chim Acta 2008;391:68-73
   PubMed Web of Science ®Google Scholar
• Parenti G, Zuppaldi A, Gabriela Pittis M, et al. Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 2007;15:508-14
   Web of Science ®Google Scholar
• Okumiya T, Kroos MA, Vliet LV, et al. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 2007;90:49-57
   PubMed Web of Science ®Google Scholar
• Flanagan JJ, Rossi B, Tang K, et al. The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat 2009;30:1683-92
   PubMed Web of Science ®Google Scholar
• Marugan JJ, Zheng W, Motabar O, et al. Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators. Eur J Med Chem 2010;45:1880-97
   PubMed Web of Science ®Google Scholar
• Xiao J, Westbroek W, Motabar O, et al. Discovery of a novel noniminosugar acid alpha glucosidase chaperone series. J Med Chem 2012;55:7546-59
   Google Scholar
• Bruckmann C, Repo H, Kuokkanen E, et al. Systematic structure-activity study on potential chaperone lead compounds for acid alpha-glucosidase. ChemMedChem 2012; Epub ahead of print
   Google Scholar
• Khanna R, Soska R, Lun Y, et al. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther 2010;18:23-33
   PubMed Web of Science ®Google Scholar
• Porto C, Ferrara MC, Meli M, et al. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine. Mol Ther 2012;20:2201-11
   PubMed Web of Science ®Google Scholar
• Porto C, Cardone M, Fontana F, et al. The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Mol Ther 2009;17:964-71
   PubMed Web of Science ®Google Scholar
• Porto C, Pisani A, Rosa M, et al. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. J Inherit Metab Dis 2012;35:513-20
   PubMed Web of Science ®Google Scholar
• Benjamin ER, Khanna R, Schilling A, et al. Co-administration with the pharmacological chaperone AT1001 increases recombinant human alpha-galactosidase A tissue uptake and improves substrate reduction in Fabry mice. Mol Ther 2012;20:717-26
   PubMed Web of Science ®Google Scholar
• Xu YH, Ponce E, Sun Y, et al. Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr Res 1996;39:313-22
   PubMed Web of Science ®Google Scholar
• Khanna R, Flanagan JJ, Feng J, et al. The pharmacological chaperone AT2220 increases recombinant human acid α-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS ONE 2012;7:e40776
   PubMed Web of Science ®Google Scholar
• Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008;134:769-81
   PubMed Web of Science ®Google Scholar
• Shimada Y, Nishida H, Nishiyama Y, et al. Proteasome inhibitors improve the function of mutant lysosomal alpha-glucosidase in fibroblasts from Pompe disease patient carrying c.546G>T mutation. Biochem Biophys Res Commun 2011;415:274-8
   Google Scholar
• Sermet-Gaudelus I, De Boeck K, Casimir GJ, et al. Ataluren (PTC124) induces CFTR protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010;182:1262-72
   PubMed Web of Science ®Google Scholar
• Finkel RS. Read-through strategies for suppression of nonsense mutations in duchenne/becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010;25:1158-64
   PubMed Web of Science ®Google Scholar
• Finkel RS. Read-through strategies for suppression of nonsense mutations in duchenne/becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J Child Neurol 2010;25:1158-64
   PubMed Web of Science ®Google Scholar
• Bartolomeo R, Polishchuk EV, Volpi N, et al. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 2013;36:363-71
   PubMed Web of Science ®Google Scholar
• Raben N, Lee E, Lee L, et al. Novel mutation in African-American patients with glycogen storage disease type II. Hum Mutat 1999;13:83-4
   Google Scholar
• Montalvo AL, Bembi B, Donnarumma M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat 2006;27:999-1006
   PubMed Web of Science ®Google Scholar
• Cardone M. Prospects for gene therapy in inherited neurodegenerative diseases. Curr Opin Neurol 2007;20:151-8
   PubMed Web of Science ®Google Scholar
• Tsujino S, Kinoshita N, Tashiro T, et al. Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum Gene Ther 1998;9:1609-16
   PubMed Web of Science ®Google Scholar
• Fraites TJ, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated vectors. Mol Ther 2002;5:571-8
   PubMed Web of Science ®Google Scholar
• Amalfitano A, McVie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA 1999;96:8861-6
   PubMed Web of Science ®Google Scholar
• Xu F, Ding E, Migone F, et al. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J Gene Med 2005;7:171-8
   PubMed Web of Science ®Google Scholar
• Xu F, Ding E, Liao SX, et al. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther 2004;11:1590-8
   PubMed Web of Science ®Google Scholar
• Sun B, Chen YT, Bird A, et al. Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus-AAV vector. Mol Ther 2003;7:467-77
   Google Scholar
• Sun B, Zhang H, Benjamin DK Jr, et al. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther 2006;14:822-30
   Google Scholar
• Kyosen SO, Iizuka S, Kobayashi H, et al. Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther 2009;17:521-30
   Google Scholar
• van Til NP, Stok M, Aerts Kaya FS, et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype. Blood 2010;115:5329-37
   PubMed Web of Science ®Google Scholar
• Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010;8:502-10
   Google Scholar
• Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Hum Mol Genet 2011;20(R1):R61-8
   PubMedGoogle Scholar
• Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5
   PubMed Web of Science ®Google Scholar
• Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6:765-72
   PubMed Web of Science ®Google Scholar
• Malinowska M, Wilkinson FL, Langford-Smith KJ, et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010;5:e14192
   PubMed Web of Science ®Google Scholar
• Douillard-Guilloux G, Raben N, Takikita S, et al. Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet 2008;17:3876-86
   Google Scholar
• Douillard-Guilloux G, Raben N, Takikita S, et al. Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet 2010;19:684-96
   PubMed Web of Science ®Google Scholar
• Foley JW, Bercury SD, Finn P, et al. Evaluation of systemic follistatin as an adjuvant to stimulate muscle repair and improve motor function in Pompe mice. Mol Ther 2010;18:1584-91
   Google Scholar
• Raben N, Schreiner C, Baum R, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 2010;6:1078-89
   PubMed Web of Science ®Google Scholar
• Ashe KM, Taylor KM, Chu Q, et al. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. Mol Genet Metab 2010;100(4):309-15
   PubMed Web of Science ®Google Scholar
• Sardiello M, Palmieri M, di Ronza A, et al. A gene network regulating lysosomal biogenesis and function. Science 2009;325:473-7
   PubMed Web of Science ®Google Scholar
• Medina DL, Fraldi A, Bouche V, et al. Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Dev Cell 2011;21:421-30
   PubMed Web of Science ®Google Scholar
• Spampanato C, Feeney E, Li L, et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med [Epub Apr 18, 2013]
   Google Scholar